PolyPeptide Group AG (LON:0AAJ)

London flag London · Delayed Price · Currency is GBP · Price in CHF
25.08
-0.53 (-2.07%)
Dec 19, 2025, 12:28 PM BST
-15.43%
Market Cap796.20M
Revenue (ttm)316.17M
Net Income (ttm)-29.76M
Shares Outn/a
EPS (ttm)-0.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,557
Average Volume13,608
Open25.45
Previous Close25.60
Day's Range25.08 - 25.75
52-Week Range13.82 - 30.25
Beta1.12
RSI52.54
Earnings DateMar 12, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1952
Employees 1,362
Stock Exchange London Stock Exchange
Ticker Symbol 0AAJ
Full Company Profile

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR Financial Statements

News

Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain

Lupin Manufacturing Solutions (LMS), a subsidiary of pharma giant Lupin Limited, has entered into a long-term strategic alliance with PolyPeptide...

7 days ago - Business Upturn